A 26‐week, placebo‐ and pioglitazone‐controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus

Abstract

In subjects with suboptimally controlled T2DM, rivoglitazone 1.5 mg was associated with statistically superior glycaemic control to pioglitazone 45 mg, while rivoglitazone 1.0 mg was non-inferior; the safety profiles of the two drugs appeared similar.